Q-omics provides the consensus-scored HSD3BP1 profile across patient tissues and cancer cell-line models. HSD3BP1 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, HSD3BP1 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, HSD3BP1 RNA expression shows 12,582 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRP, KIRC, and GBM as cancer lineages where HSD3BP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSD3BP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSD3BP1 survival associations across molecular data types. HSD3BP1 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSD3BP1 RNA expression–survival associations across cancer types. High HSD3BP1 expression shows unfavorable associations in KIRP, THCA, ACC, MESO and LUAD, but favorable associations in LUSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for HSD3BP1 RNA expression.
This table summarizes HSD3BP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HSD3BP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSD3BP1 shows lower tumor expression in BRCA, COAD, KIRP and CHOL and higher tumor expression in KIRC and BLCA. The KIRC box plot shows higher HSD3BP1 RNA expression in tumor versus normal tissue (log2 FC = +0.045, t-test p = .004).
This table shows molecular features associated with HSD3BP1 in patient tissues and cancer cell lines. In patient samples, HSD3BP1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
